Monday, February 22, 2016

Health Affairs Briefing: The Evolving Landscape Of Physician Practice

Recurring Topic Image - Events (640 x 360 at 72 PPI)

You are invited to join Health Affairs for our March 2016 issue briefing at which we will highlight a group of articles related to how physicians practice medicine. Specific topics include the cost to physician practices of tracking and reporting on quality measures, trends in provider payment methods, public reporting of surgeons outcomes data, reducing hospital readmissions, and trends in physician attitudes on the changing landscape of physician practice.


WHEN:

Tuesday, March 8, 2016

9:00 a.m. 10:30 a.m.


WHERE:

National Press Club

529 14th Street NW

Washington, DC (Metro Center)


Register Today!


You may follow live Tweets from the briefing @Health_Affairs,and join in the conversation with #HA_Physicians.


The forum will take place on Tuesday, March 8, 2016, at the National Press Club in Washington, D.C., and the program will feature presentations from the following authors:



  • Elaine M. Burns, Honorary Clinical Lecturer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, on Understanding The Strengths And Weaknesses Of Public Reporting On Surgeon-Specific Outcome Data

  • Lawrence P. Casalino, Livingston Farrand Professor, Department of Healthcare Policy and Research, Weill Cornell Medicine/New York Presbyterian Hospital, on US Physician Practices Spend $15.4 Billion Annually To Report Quality Measures

  • Carolyn Dickens, Cardiology Nurse Practitioner, University of Illinois Hospital & Health Sciences System, on Narrative Matters: Mr. G And The Revolving Door: Breaking The Readmission Cycle At A Safety-Net Hospital

  • Phil Miller, Vice President for Communications, Merritt Hawkins and Staff Care, on The Medical Professions Future: A Struggle Between Caring For Patients And Bottom-Line Pressures

  • Samuel H. Zuvekas, Senior Economist, Center for Financing, Access and Cost Trends, Agency for Healthcare Research and Quality, on Fee-For-Service, While Much Maligned, Remains The Dominant Method For Physician Visits


Health Affairs is grateful to the Physicians Foundation for its generous support of these articles and the event.

How Not to Research ACOs


flying cadeuciiIn Part I of this series I noted that we have almost no useful information on what ACOs do that affects cost and quality. I described two causes of that problem: The amorphous, aspirational definition of ACOs, and the happy-go-lucky attitude toward evidence exhibited by ACO proponents and many analysts. I showed how the flabby definition of ACO makes it impossible to operationalize this thing to reduce it to testable components. And I asked why the health policy community let ACO proponents get away with such a vague description of the ACO. I said the answer lies in the permissive culture of the US health policy community. It is a culture that tolerates, even encourages, the promotion of vague concepts and a cavalier attitude toward evidence.


In this installment, I illustrate these problems the vague definition of ACO, and loose standards of evidence by examining a paper published last month by the Center for Health Care Strategies (CHCS) entitled, Accountable Care Organizations: Looking back and moving forward.In the third installment of this series I will describe the emergence of the health policy culture that tolerates intellectually flabby proposals and a devil-may-care attitude toward evidence.


I chose the CHCS paper because the organization that funded it, the Robert Wood Johnson Foundation, and the organization that wrote it are prominent advocates of managed care and its latest iteration, the ACO. The Foundation describes itself as an early supporter of the idea that later became known as managed careThe Foundation announced last July it has been supporting ACOs for several years now.CHCS was established two decades ago with support from the Foundation, and receives funding from organizationsthat promote managed care and ACOs.


Moreover, the papers authors and funders made it clear they hoped the paper would provide a useful update on what ACOs have accomplished and how they accomplished it. In its July 2015 announcement of the $20,000 grant that supported this study,the Foundation said the study would inform stakeholders of progress to date by accountable care organizations. CHCSs paper claims it identifies key lessons from ACO activities across the country to date (p. 1).



Finally, I chose CHCSs paper because it was just published.


In short, if there is a paper out there that could refute my claim that we have no useful research on what ACOs do for patients that distinguishes them from non-ACO providers, this paper should be it. Its authors are experienced writers and researchers, the authors and the funder clearly wanted to cast ACOs in a favorable light, and the authors had plenty of money to search the literature and interview ACO experts.


But the paper fails to provide any useful evidence on ACOs. With two exceptions, it doesnt even resort to anecdotes, which is a common tactic among ACO proponents and analysts. (Oddly, the two anecdotes deal with the same service finding housing for homeless people.)


The paper fails to produce useful evidence for the two reasons I discussed in Part I: The authors accept the vacuous, aspirational definition of ACO; and the authors are willing to let opinion substitute for evidence.


A wish is not a definition


The paper begins with the usual wishful definition of ACO, to wit: ACOs are designed to achieve the Triple Aim by shifting varying degrees of financial responsibility for patient outcomes to the provider level. (p. 2). There are two problems with this definition: It uses manipulative language, and the language describes a wish, not an entity that can be tested and rationally debated.


The manipulative, wishful language appears in the statement, ACOs are designed to achieve the Triple Aim. Note the passive voice (are designed) and the wish expressed by this unidentified voice (to achieve the Triple Aim). Who designed the ACO and how do we know said designers knew how to invent something that simultaneously achieves three goals at once? What research guided them? How credible was that research? We arent told. Rather, we are supposed to skip over those questions and just accept the unarticulated assumption that the Original Designers knew what they were doing, and they were basing their design decisions on solid evidence, not the latest in conventional wisdom.


Secondly, this definition assumes all we need to know about ACOs is that they inflict financial risk on doctors and hospitals. Nothing further need be specified.


By accepting without criticism the conventional aspiration-based definition of ACO, CHCS guaranteed it would not be reporting any empirical evidence on ACOs. CHCS reacted to this self-inflicted quandary the same way L&M Research did (see Part I of this series), namely, by asserting that ACOs have a few abstractly defined features. Here is how CHCS described these features (note the expression of hope, the high level of abstraction, and the use of labels designed to persuade rather than inform): To achieve the Triple Aim, ACO models typically involve three overlapping components: Value-based payment methodology, quality improvement strategy, [and] data reporting and analysis infrastructure. (p. 2)


Obviously, these poorly defined, overlapping components (redundant might have been more accurate than overlapping) predict nothing about what ACO providers will do, or what services they will provide, that are different from non-ACO providers. Consider just two of the more obvious questions we need to ask about ACOs that CHCS, trapped in its self-inflicted quandary, could not answer: (1) Should ACOs deliver particular services to their sickest members or to their entire population? (2) If the answer to question 1 is ACOs should provide extra services only to their sickest members, what services should they provide?


CHCSs report sheds no light on these questions. Instead, the lessons CHCS reports amount to mere bromides. The paper contains dozens of examples. Here are three:



  • ACO efforts are often grounded in analyzing the health needs of their attributed patients (p. 4);



  • Many ACO efforts aim to achieve shared savings by eliminating inefficiencies. (p. 4); and



  • ACOs are beginning to look at ways to engage patients. (p. 9)


Notice all the hedge words in just those three sentences often, many, efforts, are beginning, and ways. When lessons are expressed so abstractly and with so many waffle words, it is fair to characterize them as useless bromides.




But arent bromides the best we can expect from research that starts out defining ACOs in terms of the wishes of their proponents?


Disinterest in rigorous evidence


Although CHCS claims it wants to provide useful evidence to ACO leaders and to policy-makers, it is clear from its paper and a subsequent blog comment that CHCSs highest priority is to cast the ACO in a favorable light and to induce policy-makers and funders to continue supporting ACOs even though the early results are not encouraging.

The evidence indicating that CHCS is more interested in promoting ACOs than analyzing them is of two types: The inferior quality of the evidence CHCS cites to support its claims; and CHCSs willingness to claim ACOs are saving money without asking what it costs insurers and ACO providers to set up and run ACOs.


The evidence CHCS cites on ACOs impact on costs consists exclusively of undocumented press releases from three state agencies.[1] Likewise, with one exception, the evidence CHCS cites with regard to quality consists of documents published outside the peer-reviewed literature.[2]


The only evidence CHCS cites for its claim that ACOs are saving money are short blurbs in two press releases and an annual report about Medicaid ACOs from three state agencies, to wit:




  • a single sentence in a sidebar of a glossy annual report published by the Colorado Department of Health Care Policy and Financing that looks and reads like an advertisement for a political candidate or a health insurance company;and



None of these documents refers the reader to studies. We simply must take the word of the government officials who wrote them that they used acceptable methods to attribute patients to ACOs, to create control groups, to risk-adjust cost and quality measures, and to detect gaming strategies such as teaching to the test and up-coding.[3]


To make matters worse, CHCS failed to cite credible research (certainly more credible than government press releases) that indicates ACOs do not cut costs. The Physician Group Practice Demonstration, which CMS ran from 2005 to 2010, is widely regarded by ACO proponents and neutral observers alike as a test of the ACO concept.That demonstration showed that the ACOs saved CMS a grand total of three-tenths of a percent after taking into account the bonus payments CMS made to ACOs (but not taking into account the expenditures ACOs and CMS incurred to set-up and run ACOs).[4]


To take one more example of research CHCS ignored: Last SeptemberKaiser Health News, using publicly available data that CHCS could have examined, reportedthat CMSs two ACO programs slightly raised Medicare costs in 2013. Again, that estimate did not take into account costs to set up and run ACOs.


The second feature of the CHCS paper which illustrates the distant relationship between ACO proponents and the usual rules of science is the papers total disinterest in determining what it costs providers and insurance companies to set ACOs up and provide the extra services ACOs allegedly provide. (This same strange habit afflicts research on other managed care fads, including medical homes and pay-for-performance.) Claiming that ACOs lower medical costs without asking what it cost ACOs and the insurers they contract with to implement the interventions that lead to lower medical costs is like claiming solar panels reduce heating bills without taking into account the cost of buying and maintaining the solar panels. It is difficult to imagine that this omission may I call it a sleight-of-hand? would be tolerated in any discipline other than health policy.


But CHCS makes no mention of this issue. The documents published by the states of Oregon, Minnesota and Vermont that CHCS cites as evidence that ACOs are saving Medicaid money did not mention this issue either.


Despite CHCSs inability to produce evidence that ACOs are working as advertised, CHCS concludes its paper with these cheerful remarks: [P]olicy-makers and funders should not be afraid to forge ahead on innovative ACO model enhancements, and they should provide key support for work toward ACO arrangements that improve quality [and] reduce costs. To make sure policy-makers and funders got this message, CHCS went on to write a blog based on this report entitled, How funders can support emerging accountable care organizations to maximize their potential.


This is not research. This is advocacy of conventional wisdom or, to put it more harshly, promotion of group think. As long as ACO proponents and analysts think their job is advocacy rather than research, the useless definition of ACO will continue to go unquestioned, and the dearth in useful research on ACOs will persist.


[1] Only three of the 42 endnotes in the CHCS paper cite peer-reviewed papers. None of these three address cost, and only one addresses quality. The three papers are: Colla et al., First national survey of ACOs finds that physicians are playing strong leadership and ownership roles,Health Affairs, June 2014;33(6); McWilliams et al, Changes in patients experiences in Medicare Accountable Care organizations,New England Journal of Medicine, October 30, 2014; and Scheffler, Accountable Care Organizations: Integrated care meets market power,Journal of Health Politics, Policy, and Law, August 2015.


[2] To its credit, CHCS concedes we have very little useful research on ACO quality because the existing research uses so few measures. While quality metrics tend to capture performance on specific outcomes., they may not accurately measure the overall health of the patient, they observe. This makes it difficult to assess the true impact and efficacy of ACO arrangements. (pp. 9-10)



Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder: A disorder in which a person is unable to control behavior due to difficulty in processing neural stimuli, accompanied by an extremely high level of motor activity. Abbreviated ADHD. ADHD can affect children and adults, but it is easiest to perceive during schooling. A child with ADHD may be extremely distractible, unable to remain still, and very talkative. ADHD is diagnosed by using a combination of parent and/or patient interview, observation of the patient, and sometimes use of standardized screening instruments. Treatments include making adjustments to the environment to accommodate the disorder, behavior modification, and the use of medications. Stimulants are the most common drugs used, although certain other medications can be effective.



MedTerms (TM) is the Medical Dictionary of MedicineNet.com.
We Bring Doctors' Knowledge To You

Sunday, February 21, 2016

Ureaplasma

Ureaplasma: A bacterium that commonly infects the urogenital tract and can cause premature birth or spontaneous abortion. During delivery, ureaplasma can infect the newborn and cause meningitis, pneumonia, or septicemia.

Ureaplasma is similar to mycoplasma. They are among the smallest free-living organisms known. Ureaplasma lacks several proteins standard in comparable organisms. Its low biosynthetic capacity means that it must import more nutrients needed for growth that most other bacteria.



MedTerms (TM) is the Medical Dictionary of MedicineNet.com.
We Bring Doctors' Knowledge To You

Apple and the 3 Kinds of Privacy Policies


Screen Shot 2016-02-21 at 8.01.34 PM


Why Are Apple's Competitors Staying Silent On the iPhone Unlocking Fight? is the question of the day on tech blogs. The answer is hardly technical and may not be legal, it's all about privacy policies and business strategy and it is very evident in healthcare.


There are three classes of privacy policy in healthcare and everywhere else:


Class 1 - "Apple will not see your data." This is Apple's privacy policy for ResearchKit and HealthKit and apparently for whatever data the FBI is hoping to read from the terrorist's phone. Obviously, in this case the person is in complete control of the data and it can be shared only with third-parties that the person authorizes.


Class 2 - "We will see and potentially use your data but you will have first-class access to your data". This is the kind of privacy policy we see with Apple's calendar and many Google services. The personal data is accessible to the service provider but it is also completely accessible via an interface or API. In healthcare, the equivalent would be having the FHIR API equally and completely accessible to patients and to _any_ third-parties authorized by the patient. This is Patient Privacy Rights' recommendation as presented to the API Task Force.


Class 3 - "We will use your data according to xyz policy and if you don't like it, take your illness elsewhere." This is pretty much how healthcare and much of the Web world runs today. We have limited rights to our own data. On the other hand, the services that have our data can sell it and profit in dozens of ways. This includes selling de-identified data. In Class 3, you, the subject of the data are a third-class citizen, at best. In many cases, the subject doesn't even know that the data exists. See, for example, The Data Map.


We are so completely engulfed by Class 3 privacy policies that we have lost perspective on what could or should be. A Class 1 policy like Apple's is widely seen as un-American. A Class 2 policy like PPR's is indirectly attacked as "insurmountable".



The reality is that technology moves much faster than other parts of our society. Whether it's encryption to secure iPhones so "Apple will not see your data." or CRISPR to control Zika Virus, we need to plan for tomorrow's technology today. In healthcare, that means encouraging businesses and health care services that adopt Class 1 and Class 2 privacy policies.


HIE of One, an open source technology project by Michael Chen, MD and myself, is a current proof of concept of how Class 2 privacy policies could transform healthcare in just a couple of years. This THCB post and this 14-minute video demonstrate that a patient-centered health IT architecture is possible with today's technology. Turning the HIE of One proof of concept into reality is taking place in our HEART workgroup and will be the subject of many conversations with health industry vendors and regulators at HIMSS next week.

Saturday, February 20, 2016

Aspirin

Aspirin: Once the Bayer trademark for acetylsalicylic acid, now the common name for this anti-inflammatory pain reliever.



MedTerms (TM) is the Medical Dictionary of MedicineNet.com.
We Bring Doctors' Knowledge To You

Friday, February 19, 2016

CMS is Largely Why we Have so Little Useful ACO Research


flying cadeuciiIn his THCB essay, "Why We Have So Little Useful Research on ACOs," Kip Sullivan correctly notes we know surprisingly little about the ACO program. (While he identifies Medicare, Medicaid and commercial plan ACOs, here I'm referring specifically to the Medicare Shared Savings Program (MSSP) ACOs that account for two-thirds of all ACOs.) Why there is little useful research is however not due to the two reasons Mr. Sullivan proposes. To understand why we lack useful ACO research look no further than the agency that manages the MSSP.


Mr. Sullivan's explanations are: since ACOs have been defined amorphously or aspirationally they cannot be assessed based on a prescribed set of activities or services; and, policy analysts have been "cavalier" program performance-related evidence. Neither explanation is correct. Medicare ACOs are defined regulatorily in great detail. This fact is made obvious by the, to date, 430-relevant Federal Register pages. Generally defined MSSP ACOs are a model of care delivery that increasingly shifts financial risk from the payer to the provider in order to reduce spending growth and, though less definitively determined, improve care quality and patient health outcomes. An MSSP ACO's "prescribed activities" are simply to provide beneficiaries all necessary Medicare Part A and B services. To define them beyond that or to expect the same precision or efficacy in delivering timely, comprehensive, population-based health care as administering a single prescription drug, as Mr. Sullivan would like, is impossible. Arguing ACO researchers or stakeholders are "cavalier" about how best to define and measure the program ignores, among other things, the fact CMS received over 1,670 comment letters in response to the agency's 2011 and 2014 proposed MSSP rules.



In arguing MSSP ACOs have no prescribed set of activities, Mr. Sullivan cites L&M Policy Research's evaluation of the Medicare Pioneer ACO demonstration funded by CMS. L&M's primary purpose was to determine if the 32 Pioneer ACOs reduced Medicare expenditures in their first two performance years, or in 2012 and 2013. L&M found they did. How they did this was less clear. As Mr. Sullivan notes, the best L&M could determine was lower spending growth appeared to have some relationship to greater provider engagement. This does not demonstrate L&M's research was, as Mr. Sullivan states, "useless," or prove ACOs are amorphously defined. L&M's research simply lends further evidence to the fact how providers achieve spending efficiency varies as widely as their patients and the quality of their interactions with them. Performance also varies because, among numerous other variables, providers range widely in their risk contracting experience, health information technology expertise and care coordination capabilities. To assume spending efficiency can be predetermined or attained via a prescribed set of activities is to assume reasons are causes. Any set of prescribed activities or services will not work equally well between and among providers.


Consider, instead, what CMS has done to enable providers to inform CMS about how best the agency can redefine the MSSP and improve providers' own understanding of the program.


Recently, CMS published the agency's third proposed MSSP ACO rule. The program's first rule, that established the program, was finalized in November 2011. The second rule was made final last June. The current proposed rule, published in January and will likely be finalized this summer, attempts to improve how ACO financial benchmarks are calculated - the single most important factor in determining the program participation and success. CMS has also revised twice the MSSP ACO program's quality performance measure set via annual physician fee schedule rule making. All this rule making is to CMS's credit. The agency is engaged in the difficult task of creating an Affordable Care Act-mandated program that will attract substantial provider participation, improve quality and substantially reduce Medicare spending growth. The program is based on one related demonstration, the physician group practice demonstration, that achieved at best modest success.


Credit aside, CMS nevertheless has made it inexplicably difficult for providers and policy analysts to understand how the MSSP model works operationally thereby compromising stakeholder ability to comment intelligently on how best to improve the model. For example, the current proposed rule provides not a single example to illustrate the many proposed computational changes to resetting and updating a MSSP ACO's financial benchmark. Specifically, how the agency proposes to use a regional/historical spending ratio to reset and update benchmarks and several other changes including how exactly CMS will recalculate a historical benchmark during an agreement period when a MSSP ACO's provider composition changes thereby changing the ACO's assigned beneficiary population. Since there are no examples it's impossible for providers to model with any confidence what these changes would mean to them. In addition, CMS provides no evidence for commenters to evaluate how or why the agency's proposed financial benchmarking and related changes will improve the model, facilitate improved provider performance and save the Medicare program money. In addition, CMS is also not planning to conduct any public forums to discuss the proposed rule. Well aware providers have complained for years about not having the ability to do their own financial analysis, CMS finally last October began to make available historical benchmark expenditure, average expenditure by enrollee type and risk score data to allow providers and policy analysts to trend or impute future financial performance benchmarks.


Apart from the black box aspect of ACO rule making, it appears CMS is not conducting an ongoing evaluation of the MSSP. The agency to date has made no mention of conducting one. Beyond the absence of an ongoing evaluation, CMS has made known little evaluative evidence about the program. Of the limited number of MSSP public use date files CMS has posted, the two files that provides performance year (PY) data for 2013 and 2014 (PY 2015 data will be available late this summer) only provide generated savings and losses and quality score performance information. CMS has conducted two webinars, advertised to ACO participants only, to discuss PY1 and PY2 results. What performance assessment data is presented during these webinars is very limited. For example, ACO utilization data amounts to a few slides comparing 12 utilization variables by ACOs that earned shared savings to those whom did not. CMS provides no supportive narrative and the slides presented are made available to ACO program participants only. CMS's MSSP web portal and the agency's MSSP newsletter, that provides program updates and upcoming webinar announcements, is also only accessible or available to MSSP participants only.


The MSSP has become the backbone of Medicare and payment reform generally. ACOs are Secretary Burwell's best hope to accomplish the Medicare program's quality and value payment goals. More broadly, the Medicare program is considered the market maker. Medicare CMS's unwillingness to be more transparent is therefore disappointing. It is also difficult to reconcile how a program that is about moving Medicare providers to risk contracting is managed in such a way that, ironically, provider participants and participant hopefuls have been left unable to determine their risk capabilities. As a result there has developed an apprehension about the program's future. This likely explains why a third of MSSP participants dropped out this past December, why providers willing to participate almost uniformly refuse to sign an at risk MSSP contract despite CMS's continuing efforts to offer them payment waivers and other incentives and why providers, knowing the Medicare program is inexorably moving to risk contracting, are increasingly interested in CMS's other risk bearing program, Medicare Advantage.


David Introcaso is a healthcare policy consultant based in Washington DC. David's acute care experience is via DC General Hospital and in post acute via in part his work with National Hospice and Palliative Care Organization, he consulted with a wide array of clients including the American Heart Association and the American Public Health Association and has taught as an adjunct at the University of Chicago and George Washington University. Over the past four years David has interviewed over 90 health care experts in producing independently a health care policy podcast

Adult ADHD

Adult ADHD: Attention deficit hyperactivity disorder (ADHD) as found in the adult population. ADHD is a well-known childhood disorder that is characterized by varying degrees of hyperactivity, impulsivity, and/or inattention that lead to difficulty in academic, emotional, and social functioning. Children who are diagnosed with ADHD may continue to exhibit symptoms that persist into adulthood. In the 1970s, the condition began to be diagnosed in adults who never received the diagnosis as children but displayed many of the characteristic symptoms. While up to 5% of school-aged children are believed to have ADHD, its prevalence in the adult population is difficult to estimate, but is likely to be in the range of 1%-5% of the population. Symptoms of ADHD in adults can include difficulty following directions, problems information, difficulty with concentration, and trouble with organizing tasks or completing work within time limits. Treatment, as in the pediatric population, can involve both behavioral therapies and medications.



MedTerms (TM) is the Medical Dictionary of MedicineNet.com.
We Bring Doctors' Knowledge To You

States Taking Action To Break The Link Between Chronic Disease And Maternal Death

Blog_pregnancy_anesthesia

It's shocking that maternal deaths in the U.S. are on the rise, even as they have declined nearly everywhere else in the world. One explanation for this disturbing trend is the increase in chronic conditions -- especially hypertension, diabetes, and obesity. Women who die from pregnancy or childbirth complications have disproportionately high rates of chronic disease. These health conditions now afflict more than a quarter of all pregnant women in the U.S.


Enhancing Maternal Mortality Review Boards In The U.S.


Learning from an unexpected death is an effective way to prevent future loss. When a woman dies during pregnancy, childbirth, or the postpartum period, the cause of death reported on the death certificate does not tell the full story. These situations require an in depth review to understand what happened so we can help save other women's lives.


Regrettably, only about half of states in the U.S. have a maternal mortality review board in place, and many of these states do not act on the findings from the deaths they examine.


Maternal mortality review boards (MMRBs)--composed of an interdisciplinary group of experts--have been successful in driving efforts to improve maternal care in countries as diverse as the United Kingdom, South Africa, Malaysia, and Sri Lanka. After a maternal death, best practice dictates that a review board conduct a confidential evaluation to identify the root cause of the tragedy. The team reviews case files and interviews family members and friends to understand what happened, rather than to place blame. These findings often help shed light on systemic problems that, if addressed, could prevent future deaths.


In 2013, with support from Merck for Mothers--a global initiative to end preventable maternal deaths--the Association of Maternal and Child Health Programs is strengthening review boards nationwide. The Every Mother Initiative is helping states build their capacity to routinely analyze deaths and apply the findings to change policies and practices that could save women's lives.


State Review Boards Take Action


Over the past two years, 12 states were selected to participate in the Every Mother Initiative (Note 1). In addition to sharing best practices, each state developed a program to address a leading cause of maternal death among its population. Several review teams chose to focus on the increasing prevalence of chronic conditions among women of reproductive age, given that many of the women who died in their states had untreated chronic health problems. The states' response to this problem has national implications for efforts to improve women's health before, during, and after pregnancy. Here are some examples of new statewide initiatives underway to reduce maternal mortality:


Georgia


The Georgia Maternal Mortality Review committee found that women who had chronic and complex medical conditions were not receiving the information and support they needed to avoid pregnancy until their health was well managed -- placing them at increased risk of death due to pregnancy.


The state maternal mortality review team partnered with Grady Health System and the Georgia Department of Public Health to test a new toolkit to help health care providers working in clinics in low-income communities provide counseling to patients on reproductive life planning and contraception. The toolkit includes a video on pregnancy and chronic conditions that is shown regularly in clinic waiting rooms, patient flyers with conversation prompts about chronic disease management, and recorded provider lectures to support an effective family planning counseling and referral process.


North Carolina


The North Carolina Pregnancy-Related Mortality Review team learned that a disproportionate number of maternal deaths in the state were due to complications related to cardiovascular disease and hypertension, and that many women were unaware of how their heart health might affect pregnancy.


In response, the team partnered with state-wide programs to prevent chronic disease and improve preconception health, developing the Show Your Heart Some Love social marketing campaign. The campaign targets women of reproductive age, urging them to follow a healthy lifestyle to ensure that a healthy heart comes before pregnancy. Through a short self-assessment, women can determine specific areas to focus on, such as weight-loss, diet improvements, and stress reduction to optimize heart health before pregnancy and childbirth.


Oklahoma


The Oklahoma Maternal Mortality Review Committee identified pregnancy-induced hypertension and hemorrhage as major contributors to maternal mortality and morbidity in the state. To prevent further deaths and disabilities from these causes, the Oklahoma Perinatal Quality Improvement Collaborative, in partnership with the Oklahoma State Department of Health and the Oklahoma Health Care Authority, designed and launched a hospital-based maternal safety quality improvement initiative.


This initiative is recruiting hospitals throughout the state to adopt a set of guidelines for identifying, treating, and responding to complications related to hypertension and hemorrhage during pregnancy. The guidelines are evidence-based, adapted from quality improvement efforts in California and New York, and endorsed by the Council on Patient Safety for Women's Health Care.


Looking Forward


It's encouraging to see the progress the 12 states are making to improve maternal health by learning about the circumstances of pregnancy and childbirth-related deaths. The potential impact is significant because these states account for over a quarter of the four million births in the U.S. each year. Their smart approach will hopefully lead to more effective maternal care for women in these states and beyond.


Each woman's death is a tragedy. We should not compound such a loss by failing to understand what went wrong or failing to act on what we've learned. Likewise, it's important to take advantage of the window of opportunity that pregnancy provides, especially for women with chronic health conditions. These nine months are an ideal time to help a woman develop a healthier lifestyle, strengthen the relationship with her health care team, and learn to manage her health for the long term. Care during pregnancy should link closely with primary care so that after a woman gives birth, she continues to attend to her own health, not just the health of her baby.


Note 1


The states include: Colorado, Delaware, Florida, Georgia, Illinois, Louisiana, Missouri, New York, North Carolina, Ohio, Oklahoma, and Utah.

Thursday, February 18, 2016

What Accounts For The Lower Growth In Health Care Spending?

Blog_invoice

Several recent studies have examined the factors accounting for the recent slowdown in growth in real per capita health care spending. The most recent entrant to this literature is the newly published work of Dunn, Rittmueller, and Whitmire. Earlier work has identified two large categories of change as contributors to slower growth: the 2007-2009 recession, and other structural changes in the delivery and payment of health care. Understanding the relative role of these two factors is important in determining whether the slowdown is temporary or will be sustained.


The new paper by Dunn and colleagues builds on a framework that I developed with my colleagues at Emory in 2004-2005, that decomposes the growth in spending to changes in the prevalence of treated disease, spending per case treated, and population growth by medical condition. We have published several updates to this initial paper over the past ten years.


We found that the roles played by changes in treated prevalence and cost per case since the mid-1980s differ by time period and by payer. Rising treated prevalence has consistently been the major driver of rising Medicare spending over time, while prevalence plays a smaller role in growth in private health insurance spending. Understanding the factors that account for these variations over time may provide useful information in projecting trends in health care spending.


Dunn and colleagues examine data from 2000-2005 and 2005-2010 using the aforementioned decomposition. They conclude that the spending slowdown observed between 2005 and 2010 was traced largely to lower growth in cost per case. The reductions differed, however, by medical condition. One of their conclusions is that reduced growth in cost per case is linked, in part, to blockbuster drugs, such as Norvasc and Toprol XL to treat hypertension, which came off patent during the 2005 to 2010 time period.


Indeed, our tabulations show that nominal spending on hypertension during this period actually declined by $2 billion. Patent expirations have assumed an even more important role more recently, as $84 billion worth of branded drugs came off patent between 2010 and 2013 alone. Tracking trends in drugs scheduled to come off patent will provide important information regarding future spending trends.


Several other factors could also underlie the slowdown in the growth in treated prevalence and spending per case treated going forward. On the spending side, delivery system reforms and the migration away from fee-for-service payment are structural changes that will continue to put downward pressure on growth in spending per case. These reforms include bundled payments that provide incentives for more efficient placement of patients in post-acute care settings and reductions in readmissions and the costs of the initial hospitalization. Understanding the role of these shifts in the site of treatment will be helpful in projecting future spending trends.


Several other factors are likely to affect trends in treated prevalence. Most important may the recent slowdown in the growth in obesity rates, which will affect both the incidence and prevalence of several chronic conditions. There is already some evidence that the incidence and prevalence of diabetes has leveled off between 2008 and 2012. Tracking the role of changes in chronic disease incidence and prevalence overall and by payer will provide useful information in determining whether the slower growth in spending is short lived or may continue.


Adding these epidemiologic prevalence trends to the more traditional national health account projections methodology may enable more precise health care spending projections overall and by source of treatment.

Fostering New Connections Among Health Researchers To Promote Diversity And Inclusion In Academia

Featured Topic Image - Grantwatch (640 x 360 at 72 PPI)

Building a Culture of Health for America is contingent on cultivating a diverse and inclusive community of faculty and researchers. Yet, when one extrapolates from data in a 2015 article in the Digest of Education Statistics, faculty of color represent only one in five of all full-time academics.


Recognizing the need to diversify and enrich perspectives in health and health care programming, the Robert Wood Johnson Foundation (RWJF) founded New Connections, a program for junior and midcareer scholars from historically underrepresented backgrounds.


The RWJF launched New Connections in 2005 with a three-year, $2.2 million grant. Since the inception of New Connections, the RWJF has invested approximately $20 million in funding for its program services and operations, and nearly $10 million in its research awards. New Connections has partnered with the RWJF's Healthy Eating Research program (2007-present), Public Health Law Research program (2010-2017), and Active Living Research program (2008-2013) to extend additional grant opportunities. The New Connections program releases an annual call for proposals.


Over the past ten years, New Connections has funded 137 junior and midcareer investigators attending to the most current health issues. Funded scholars use asset-based approaches, which place the voices of communities at the forefront, contribute to equitable health policies and practices, and improve health outcomes. Scholarly contributions promote healthy communities spanning geographic regions and localities in the United States.


Health disparities are avoidable, and can be substantially narrowed with culturally tailored interventions. The RWJF acknowledges that promoting a Culture of Health requires cross-cultural, interdisciplinary perspectives. Thus, New Connections engages a network of scholars who are from an underrepresented racial or ethnic group, from a low-income background, and/or the first to attend college in their family. Additionally, the program serves scholars trained in social and behavioral sciences, including public health, medicine, psychology, social work, and sociology, as well as those in architecture, business, engineering, and urban planning, whose work intersects with health.


Grantees attend to an array of research topics, including mental and emotional wellness, the built environment and obesity prevention, neighborhood safety, violence prevention, and substance abuse prevention. In addition, scholars' research emphasizes the provision of equitable health care access and delivery, in such areas as patient-provider interactions, health care coverage, and health technology. The program has also awarded funding for studies on workforce diversity, equity and inclusion, and pipeline development for health care programs.


New Connections understands that faculty from underrepresented backgrounds--particularly early career scholars--encounter unique challenges navigating "the academy." Therefore, the program focuses on fostering the growth of a diverse talent pool in the academy by investing in the career development of junior (0-10 years of experience after a doctoral degree) and mid-career (10-15 years of experience since completion of their most recent graduate degree) investigators through skill-building workshops, mentoring, and networking. More than 800 scholars have received network career services. By participating in our annual Symposium and/or Research and Coaching Clinic, participants can develop relationships with other researchers with common interests and, subsequently, collaborate on projects.


New Connections partners with seasoned researchers to serve as mentors and workshop facilitators for professional development opportunities, including in-person sessions and webinars focusing on methodology, grant writing, manuscript preparation, and leadership development, as well as "speed mentoring" sessions (where New Connections scholars spend short amounts of time meeting with senior scholars who provide mentorship and career advice).


The program also collaborates with senior administrators at academic institutions to elevate the discourse on the institutional impact of scholars from underrepresented backgrounds. A main component of these discussions is the identification and implementation of support systems that position scholars to succeed and champion the next generation of scholars influencing health and health care policy and practice. Thus, New Connections serves as a vehicle for building and sustaining the pipeline of minority faculty whose research is critical for promoting healthy communities.


In 2016, New Connections is celebrating its tenth anniversary with a year-long campaign, "Equity. Contribution. Community: New Connections at 10." The campaign will focus on the impact our scholars have made in their professions and, through New Connections-funded research, in the communities they serve.


The RWJF New Connections program helps build upon the strengths and assets of underrepresented scholars who in turn, through their research, serve as change agents by imparting innovative solutions to complex health problems and thus help build a Culture of Health.


For more information about New Connections funding and network services, visit www.rwjf-newconnections.org or email info@rwjf-newconnections.org.

Electronic Health Records: From Ebola to Zika, Fighting the Last War


flying cadeuciiWhen I showed up at the obstetrical urgent care unit at Brigham and Women's Hospital, the care I received was swift and appropriate. I saw a nurse quickly and a doctor soon after. They asked relevant questions and immediately put a plan for further evaluation in place. Only then did the nurse turn to the computer to enter everything into the electronic record. As she worked her way through the required documentation, she asked several more questions. Any allergies that weren't already in the system? Surgeries she should note? And, of course, importantly, had I been to an Ebola-infected country recently?


In September 2014, Texas Health Presbyterian Hospital missed acting upon the fact that a patient had just returned from West Africa, even though it was documented in his record. He came down with Ebola, but wasn't treated with appropriate precautions, and many patients and staff were put at risk. The hospital was publicly criticized for its behavior. The hospital administration responded by blaming its electronic health records (EHR), since the system didn't bring the travel history to the forefront as part of the doctor's workflow. Since then, hospitals have scrambled to systematically screen for the often-fatal virus that took more than 10,000 lives in the past three years. Hospitals have incorporated a relevant screening question into their EHR, like the one I was dutifully asked during my recent urgent care visit. A win for technology and public health?



Not exactly. First of all, each hospital had to implement the question themselves. Different sites are asking different questions, sometimes only in the emergency department, other times elsewhere. Hospitals implemented them at different times, some more swiftly than others. Importantly, a year ago already, the World Health Organization (WHO) was tracking fewer than 100 new cases of Ebola per week. As of December 2015, Guinea, Liberia, and Sierra Leone had stopped the chain of transmission, and the Centers for Disease Control (CDC) removed enhanced precautions for people traveling to those countries. And all in all, though many did die in this terrible epidemic, there were only tens of cases of Ebola treated outside Africa, mostly aid workers transported home, and no new cases diagnosed in the United States since 2014. The WHO reported only 7 cases and 1 death outside Africa, none of which were recent. And yet many hospitals in the United States are still asking every emergency patient if they've traveled to Africa.


But what aren't they asking? Well, as a pregnant woman, they should have asked me whether, at any time during my pregnancy, I had traveled to any countries with Zika, a virus that is transmitted to people by mosquitoes, thought to be connected to birth defects in pregnant women, and currently spreading rapidly throughout South and Central America.


But hospital EHRs are not yet prompting for Zika-related screening. It will likely take a while, and maybe a public embarrassment like what happened in Texas, for the electronic systems to be modified to include a new screening question. Does this process need to be so slow? Why should each hospital's IT staff have to manually update every public health question? Requiring each individual system to change the same setting is by design inefficient and prone to delays, inaccuracies, and inconsistencies. And yet this is how it is done today: manual decisions, site by site, slowed by different administrative and technical hurdles.


Instead, using infrastructure already in place like WHO and CDC guidelines, the public health authorities could easily set up a system that automatically incorporated alerts in a timely way. Kenneth D. Mandl and Isaac S. Kohane argued for this years ago, asking why hospital systems must reinvent everything themselves, like spell check and word processing and mapping: "Only a small subset of loosely coupled information technologies need to be highly specific to health care. Many components can be generic." That is, instead of demanding that hospitals or EHR vendors be public health experts, why can't the CDC do what it does best and automatically push its information out to everyone?


Of course, individual institutions have different needs. There could be a delay in implementation pending approval by the appropriate hospital committee, but if the hospital committee didn't take action to opt out or modify it for individual needs, the alert could by default be put into place, meaning no hospital would miss an important alert. Similarly, no longer could relevant questions be pulled without hospitals worrying about being the first to stop the screening, which is the current situation and leads to the risk of adding but never subtracting screening questions. Instead of waiting for everyone to catch up on the weekly Morbidity and Mortality Weekly Report, which in late January recommended that, "Health care providers should ask all pregnant women about recent travel," providers across the country could be confident that their daily tools always reflect best public health practices. Indeed, just last week the CDC updated their guidelines again, recommending that providers caring for pregnant women who have traveled to areas with ongoing Zika virus transmission should be offered serologic testing, even if asymptomatic. It is unreasonable to expect individual providers or even hospitals to keep up on their own.


The Ebola virus is more fatal and in many ways was much scarier than any current virus, but the more scientists learn, the more they realize how much more difficult it may be to contain Zika. Thus it should be "out with Ebola, in with Zika," in terms of questions for all pregnant women.


The existing system is too slow to respond and when it does, it finds itself chasing the past. Like security protocols at airports, where travelers are required to remove shoes because someone in 2001 hid explosives in his sneaker soles, instead of anticipating the next creative attack, the U.S. public health system finds itself asking about yesterday's Ebola and not today's Zika, because the gears of change move too slowly. But the limitation is not the technology. Technology systems should be the first to respond, even more quickly than official government responses. They should be deployed more nimbly to support faster, more informed decisionmaking. Just as my iPhone automatically receives Amber Alerts as soon as they are issued by authorities, EHR could easily reflect the most relevant public health issues. It is shocking that health care providers are still asking about Ebola when Zika is already all over the news. The tools and the technology exist, but smarter ways to use them must be implemented.


Shira Fischer is an associate physician researcher at the nonprofit, nonpartisan RAND Corporation.

Wednesday, February 17, 2016

Electronic Health Records: Yesterday's Ebola and Today's Zika


flying cadeuciiWhen I showed up at the obstetrical urgent care unit at Brigham and Women's Hospital, the care I received was swift and appropriate. I saw a nurse quickly and a doctor soon after. They asked relevant questions and immediately put a plan for further evaluation in place. Only then did the nurse turn to the computer to enter everything into the electronic record. As she worked her way through the required documentation, she asked several more questions. Any allergies that weren't already in the system? Surgeries she should note? And, of course, importantly, had I been to an Ebola-infected country recently?


In September 2014, Texas Health Presbyterian Hospital missed acting upon the fact that a patient had just returned from West Africa, even though it was documented in his record. He came down with Ebola, but wasn't treated with appropriate precautions, and many patients and staff were put at risk. The hospital was publicly criticized for its behavior. The hospital administration responded by blaming its electronic health records (EHR), since the system didn't bring the travel history to the forefront as part of the doctor's workflow. Since then, hospitals have scrambled to systematically screen for the often-fatal virus that took more than 10,000 lives in the past three years. Hospitals have incorporated a relevant screening question into their EHR, like the one I was dutifully asked during my recent urgent care visit. A win for technology and public health?



Not exactly. First of all, each hospital had to implement the question themselves. Different sites are asking different questions, sometimes only in the emergency department, other times elsewhere. Hospitals implemented them at different times, some more swiftly than others. Importantly, a year ago already, the World Health Organization (WHO) was tracking fewer than 100 new cases of Ebola per week. As of December 2015, Guinea, Liberia, and Sierra Leone had stopped the chain of transmission, and the Centers for Disease Control (CDC) removed enhanced precautions for people traveling to those countries. And all in all, though many did die in this terrible epidemic, there were only tens of cases of Ebola treated outside Africa, mostly aid workers transported home, and no new cases diagnosed in the United States since 2014. The WHO reported only 7 cases and 1 death outside Africa, none of which were recent. And yet many hospitals in the United States are still asking every emergency patient if they've traveled to Africa.


But what aren't they asking? Well, as a pregnant woman, they should have asked me whether, at any time during my pregnancy, I had traveled to any countries with Zika, a virus that is transmitted to people by mosquitoes, thought to be connected to birth defects in pregnant women, and currently spreading rapidly throughout South and Central America.


But hospital EHRs are not yet prompting for Zika-related screening. It will likely take a while, and maybe a public embarrassment like what happened in Texas, for the electronic systems to be modified to include a new screening question. Does this process need to be so slow? Why should each hospital's IT staff have to manually update every public health question? Requiring each individual system to change the same setting is by design inefficient and prone to delays, inaccuracies, and inconsistencies. And yet this is how it is done today: manual decisions, site by site, slowed by different administrative and technical hurdles.


Instead, using infrastructure already in place like WHO and CDC guidelines, the public health authorities could easily set up a system that automatically incorporated alerts in a timely way. Kenneth D. Mandl and Isaac S. Kohane argued for this years ago, asking why hospital systems must reinvent everything themselves, like spell check and word processing and mapping: "Only a small subset of loosely coupled information technologies need to be highly specific to health care. Many components can be generic." That is, instead of demanding that hospitals or EHR vendors be public health experts, why can't the CDC do what it does best and automatically push its information out to everyone?


Of course, individual institutions have different needs. There could be a delay in implementation pending approval by the appropriate hospital committee, but if the hospital committee didn't take action to opt out or modify it for individual needs, the alert could by default be put into place, meaning no hospital would miss an important alert. Similarly, no longer could relevant questions be pulled without hospitals worrying about being the first to stop the screening, which is the current situation and leads to the risk of adding but never subtracting screening questions. Instead of waiting for everyone to catch up on the weekly Morbidity and Mortality Weekly Report, which in late January recommended that, "Health care providers should ask all pregnant women about recent travel," providers across the country could be confident that their daily tools always reflect best public health practices. Indeed, just last week the CDC updated their guidelines again, recommending that providers caring for pregnant women who have traveled to areas with ongoing Zika virus transmission should be offered serologic testing, even if asymptomatic. It is unreasonable to expect individual providers or even hospitals to keep up on their own.


The Ebola virus is more fatal and in many ways was much scarier than any current virus, but the more scientists learn, the more they realize how much more difficult it may be to contain Zika. Thus it should be "out with Ebola, in with Zika," in terms of questions for all pregnant women.


The existing system is too slow to respond and when it does, it finds itself chasing the past. Like security protocols at airports, where travelers are required to remove shoes because someone in 2001 hid explosives in his sneaker soles, instead of anticipating the next creative attack, the U.S. public health system finds itself asking about yesterday's Ebola and not today's Zika, because the gears of change move too slowly. But the limitation is not the technology. Technology systems should be the first to respond, even more quickly than official government responses. They should be deployed more nimbly to support faster, more informed decisionmaking. Just as my iPhone automatically receives Amber Alerts as soon as they are issued by authorities, EHR could easily reflect the most relevant public health issues. It is shocking that health care providers are still asking about Ebola when Zika is already all over the news. The tools and the technology exist, but smarter ways to use them must be implemented.


Shira Fischer is an associate physician researcher at the nonprofit, nonpartisan RAND Corporation.

CMS Releases Final List Of 19,000 Essential Community Providers

Tim-ACA-slide

Implementing Health Reform. On February 17, 2016, the Centers for Medicare and Medicaid Services (CMS) released a final updated list of over 19,000 essential community providers (ECPs) to assist insurers in complying with the ECP requirements that apply to qualified health plans (QHPs). CMS also published a guidance describing how the list is to be used.


ECPs are providers that serve predominantly low-income, medically underserved individuals. Under the 2017 draft letter to issuers, which should be finalized shortly, insurers must contract with 30 percent of available ECPs in their service area, offer contracts in good faith to all Indian health providers in their service area, and offer contracts in good faith to at least one ECP in each of six categories of ECPs (family planning providers, federally qualified health centers, hospitals, Indian health care providers, Ryan White providers, and "other" ECPs).


The final list is non-exhaustive. QHP insurers may write in additional ECPs not on the list as long as the written-in ECP meets ECP requirements and itself petitions for ECP status no later than August 22, 2016. Insurers that do not meet the 30 percent standard may submit a narrative justification explaining how they adequately meet the needs of their low-income and medically underserved enrollees and how they intend to increase ECP participation in the future. Plans that provide services through employed or contracted medical groups or hospitals, such as staff model HMOs must meet alternative ECP standards.


Standalone dental plans must offer good faith provider contracts to at least 30 percent of the dental ECPs in its service area and to all available Indian dental health care providers in its service area. As with health insurers, a standalone dental plan unable to satisfy the 30 percent requirement may offer a narrative justification meeting specified standards.


In December of 2015 CMS undertook an initiative to update and expand the ECP list. In response to public comments received on the 2017 proposed payment rule and letter to issuers, CMS also changed the format of the ECP list for benefit year 2017 to add provider data, including the National Provider Identifier (NPI), the number of full-time equivalent (FTE) practitioners available at each facility, additional ECP category indicators, and points of contacts and phone numbers for each ECP type listed in the ECP list.

Mitochondrial disease

Mitochondrial disease: A mutation in the mitochondrial chromosome that is responsible for a disease. Known mitochondrial diseases include the eye disease Leber hereditary optic atrophy; myoclonus epilepsy with ragged red fibers (MERRF); and mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS syndrome).



MedTerms (TM) is the Medical Dictionary of MedicineNet.com.
We Bring Doctors' Knowledge To You

Tuesday, February 16, 2016

Request For Abstracts: Health Affairs Issue On Oral Health

Blog_Dental_Tech

Health Affairs is planning a December 2016 theme issue on oral health. Among other topics, we are interested in work exploring coverage, access, and utilization; disparities and special populations; workforce, training, and scope of practice; prevention; and the relationship between oral health and overall health.


We plan to publish approximately ten peer-reviewed articles including research, analyses, and commentaries from leading researchers and scholars, analysts, industry experts, and health and health care stakeholders.


We invite all interested authors to submit abstracts for consideration for this issue. In order to be considered, abstracts must be submitted by 11:59PM EST, March 8, 2016. If you wish to submit an abstract, please send it as an email attachment to HealthAffairs_Oral_Health_abstracts@projecthope.org


The issue will include at least one paper that provides an overview of the historic split between dental care and the larger medical care system and the implications of this split, with an eye toward the future of oral health care in the U.S. In filling out the issue, we are particularly interested in empirical analyses of specific policies, programs, and practices that relate to oral health in the U.S. and abroad, including papers that explore innovative models and practices to improve care.


More information on topics and themes for this issue, as well as process guidelines and timetables, is available in the request for abstracts on the Health Affairs website. Please consult our online abstract submission guidelines for additional formatting instructions and answers to frequently asked questions. If you have additional questions, please email Oral_Health_queries@healthaffairs.org. Feel free to pass this invitation along to colleagues who might be interested as well.

Why We Have so Little Useful Research on ACOs


flying cadeuciiOur country urgently needs research on the impact of "accountable care organizations" on cost and quality. The ACO has been the establishment's great hope for health care reform since the concept was invented at the November 9, 2006 meeting of the Medicare Payment Advisory Commission. If ACOs are not going to work, we need to know sooner rather than later.


Although it's been almost a decade since the ACO concept was invented and six years since Congress endorsed it, we know remarkably little about ACOs. What little reliable research we have was done on CMS's ACO programs, but even that research is woefully incomplete. As for the ACOs set up by state Medicaid agencies and insurance companies, we know almost nothing.


Yes, I know, we have a few dozen papers telling us where ACOs are starting up, whether physicians or hospitals are "leading" them, and whether their managers tells pollsters they can "monitor care across the continuum" and "have programs in place to reduce hospital admissions," etc. But we have no idea what ACOs do for patients that non-ACO providers do not do.


There are two reasons for this information vacuum. The first is the definition of the ACO. ACO proponents have never defined the ACO; they have told us only what they hope ACOs will do (they tell us they want ACOs to "hold providers accountable"). The second problem is the cavalier attitude toward evidence with which ACO proponents and analysts approach ACO research. Until the US health policy community addresses these problems, the dearth of useful research on ACOs will continue.


In this comment, I will describe these twin problems - the amorphous, aspiration-based definition of ACO, and the casual attitude toward evidence exhibited by ACO proponents and analysts. In Part II of this series I will illustrate these problems with a report on ACOs financed by the Robert Wood Johnson Foundation. The report, entitled "Accountable Care Organizations: Looking back and moving forward,"http://www.chcs.org/media/ACOs-Looking-Back-and-Moving-Forward.pdf was released last month by the Center for Health Care Strategies. In Part III I will argue that the vague definition of ACOs and the cavalier attitude toward evidence exhibited by ACO proponents is a result of a permissive culture that evolved first within the managed care movement and then spread throughout the American health policy community.



The unbearable vagueness of ACOs


The ACO has always been "defined" by the hopes of its proponents, and health policy analysts and editors have let them get away with it. Here is the typical definition of "ACO" taken from one of the earlier papers http://content.healthaffairs.org/content/29/5/982.abstract by ACO advocates, including Mark McClellan and Elliot Fisher: "ACOs consist of providers who are jointly held accountable for achieving measured quality improvements and reductions in the rate of spending growth. Our definition emphasizes that these cost and quality improvements must achieve overall, per capita improvements in quality and cost, and that ACOs should have at least limited accountability for achieving these improvements while caring for a defined population of patients."


This definition contains the ingredients common to all ACO definitions, notably, language depicting a (poorly defined) group of providers being "held accountable" (by unidentified means by unidentified parties) for "measured improvements" (measured at an unknown cost to providers and the measurer) in the "cost and quality" of (unspecified) health care services delivered to a "population." This definition tells us nothing about ACOs.


All we can divine from this "definition" are the authors' hopes for the ACO. They want providers to be held "accountable," and they want expenditures to fall and quality to go up. That's like defining a drug according to the hopes of the drug manufacturer rather than by its ingredients and the expected action of those ingredients. The aspirational definition of the ACO tells us nothing about the services ACOs will provide to patients that non-ACO providers do not deliver, and it fails to identify a single mechanism that will cause these services to be delivered.[1]


The unbearable lightness of the ACO "definition" puts researchers in a quandary. How do they test the claims made for a concept that is defined only by what the concept's promoters want the concept to achieve?


Here is how L&M Policy Research, one of CMS's contractors, described this quandary in a report https://innovation.cms.gov/Files/reports/PioneerACOEvalRpt2.pdf evaluating the first two years of the Pioneer ACO program: "The ACO 'treatment' under investigation is not a prescribed set of activities or interventions. Rather, it is a financial arrangement in which provider organizations attempt to reduce expenditures below a set target while maintaining high quality metrics in exchange for bearing risk for reducing expenditures." (p. 1) What? "Financial arrangement in which someone attempts....?" Can it get any vaguer than that?


How do investigators operationalize - reduce to testable components - this thing, this, um, "arrangement"? They can't. Pity the poor contractor, such as L&M, who has to make up something to test. Here are the "features" of ACOs L&M dreamed up to "test" in its evaluation of the Pioneer ACO program:



  • "hospital relationships,"

  • "capacity to follow and monitor beneficiaries through the care continuum,"

  • "engaged leadership,"

  • "provider engagement," and

  • "market pressures."


Notice the promiscuous use of waffle words - "relationships," "care continuum," "engaged," and "pressures." How is "market pressure" a "feature" of an ACO?


Not surprisingly, L&M offered no useful definition of these "features" (with the possible exception of "hospital relationship"). Not surprisingly, L&M found no relationship between these five "features" and spending nor between them and patient satisfaction. And what if they had? What if "provider engagement" had been correlated? What would that have told us, for example, about what ACOs do to lower, say, hospital use for their "defined population," or for particular types of patients, such as those with Alzheimer's?


L&M's useless research is not L&M's fault. It's just not possible to produce useful research about a concept defined by listing outcomes expected by the concept's proponents. My only criticism of L&M's report is that L&M failed to say what I'm saying - useful research on the ACO is not possible as long as the definition remains so amorphous. All we can do is measure cost and quality of the entities that call themselves ACOs, but since there is no "prescribed set of activities or interventions" for ACOs, as L&M put it, we can't conclude that any particular activity or intervention caused whatever impact on costs or quality our "research" found.


The managed care culture and indifference to evidence-based policy


Why did the health policy community allow a concept as poorly defined as the ACO to acquire the status of conventional wisdom? Why didn't the members of that community - scholars, members of Congress, employees of foundations such as the Commonwealth Fund and the Robert Wood Johnson Foundation, employers, and editors of professional journals - notice the problem and demand that it be addressed before the ACO skyrocketed from obscurity to national health policy?


That same health policy community would scream bloody murder if a drug company promoted a drug based on the aspirations of the drug company. The entire world, including health policy experts, would chortle if the drug company produced "research" analogous to L&M's that found, for example, that the drug company's "leadership" is "engaged." We don't care whether the drug manufacturer's leadership is "engaged." We want to know if the drug works, and if so by what mechanisms.


But the vast majority of health policy experts just can't bring themselves to apply the same standard to a health policy proposal, in this case, to the ACO? Why is that?


To answer that question, we must put the culture of health policy experts under the microscope. What is it about the culture of the US health policy community - the incentives to which they are exposed, the attitudes of their more successful members, their articulated and unarticulated mores - that induce them to tolerate, even take seriously, a proposition as vaguely defined as the ACO?


In Part III of this series I will describe this culture and its origin in more detail. Here I will describe briefly the mores of health policy experts that enabled the rise of a concept as poorly defined and documented as the ACO, an event which in turn guaranteed useful research on ACOs would be extremely difficult if not impossible to conduct.


Since the birth of the managed care movement in the early 1970s, that movement has displayed a breezy indifference to the evidence for and against its claims (for example, the claim that fee-for-service payment causes "fragmentation" and overuse of medical services, and that HMOs are the solution to the alleged fragmentation and overuse). In a paper I co-authored with Ted Marmor that we delivered at Yale Law Schoolhttps://www.nasi.org/civicrm/event/info?reset=1&id=176 late in 2014, we identified three dysfunctional characteristics of the managed care movement: "[A] penchant for unnecessarily abstract concepts, labels designed to persuade rather than illuminate ... , and assertions based on little or no evidence."


http://digitalcommons.law.yale.edu/cgi/viewcontent.cgi?article=1231&context=yjhple


The ACO fad illustrates all three characteristics:



  • The concept is very abstract;

  • its proponents gave it a label designed to manipulate rather than illuminate (it implies that the medical profession, one of the most regulated professions on the planet, is "unaccountable" and ACOs, at long last, are going to change that); and

  • there was very little evidence supporting the claims made for the ACO when it was sold to Congress and very little now.


These habits of thought were adopted by the first proponents of managed care in the 1970s, and spread rapidly throughout the health policy community, a community which emerged roughly simultaneously with the rise of the managed care movement.


The effect of these three habits is evident to some degree in nearly every paper published about ACOs. In Part II of this series I will illustrate these habits with an examination of a document that purports to be an up-to-date review of ACOs, "Accountable Care Organizations: Looking back and moving forward." http://www.chcs.org/media/ACOs-Looking-Back-and-Moving-Forward.pdf This paper was described by its authors as a study designed to provide "lessons" about ACOs based on their "initial successes." In fact, the paper provides no evidence of "successes" in controlling costs and only sparse evidence of "successes" in improving quality, and it provides no "lessons" - no useful feedback that would enable ACOs, analysts, or policy-makers to determine whether ACOs are working or failing and, if so, why,


Instead, the paper is an excellent illustration of why we have so little useful research on ACOs.


[1] The definition of the ACO in the Affordable Care Act is another example of a hope-based definition. Section 3022 states: "The ACO shall be willing to become accountable for the quality, cost, and overall care of the Medicare fee-for-service beneficiaries assigned to it."

Hiatal hernia

Hiatal hernia: An anatomical abnormality in which part of the stomach protrudes up through the diaphragm into the chest.

Normally, the esophagus passes down through the chest, crosses the diaphragm, enters the abdomen through a hole in the diaphragm called the esophageal hiatus and joins the stomach just below the diaphragm. When there is a hiatal hernia, the opening of the esophageal hiatus is larger than normal and a part of the stomach slips up or passes (herniates) through the hiatus and into the chest.

This type of hernia can be congenital (present at birth) or acquired over time. Symptoms usually start with a tingling or burning sensation, heartburn, or gastroesophageal reflux (GERD). These may require surgery, which may be emergent if blockage of the esophagus or pain is present.

Hiatal Hernia



MedTerms (TM) is the Medical Dictionary of MedicineNet.com.
We Bring Doctors' Knowledge To You

Monday, February 15, 2016

Unicornius Gorus - Theranos and Zenefits


The Lab test reinvented - Theranos


So I have to ask Theranos; which lab test have you reinvented? Is it the one where you do a full blood draw and send it off to UCSF to pay way more than the amount you charged the patient? Is there something in that business model I am not getting? Or did you reach back to the old "I'll make it up in volume" approach.


The Nation's First Modern Benefits Broker - Zenefits


And you Zenefits, if your idea of "Modern Benefits Broker" is that they are not licensed to sell insurance, I think I'll go for the pre-modern broker.Yes I know, I've heard it soooooo many times, all it takes is a bit of silicon valley whiz bang and the whole world will be better, take that unique bravado and creativity and apply it to healthcare, change the world.


Only one small problem; as Esther Dyson said at Health 2.0 many years ago and I'm paraphrasing from memory:


I'll come back in two years and most of you won't be here, why because you don't understand healthcare. You can build all the great systems you want, but if they don't work in healthcare, because you don't understand it, you're done.



Yes it's true that most of these hyped Silicon Valley products won't work in healthcare and certainly won't change the world; but now we find out that some companies may have openly ignored or flouted basic healthcare blocking and tackling, things like product filings, operational process and reporting, licensure and compliance with regulations.


So these two companies and 23andMe before them have demonstrated exceptionally well that you can get to Unicorn valuation's, by flat out ignoring or possibly working around the laws set up to protect the consumers and ensure that the products and services delivered meet standards.


I say to Silicon Valley - Bring me your innovation, your brains, your code, your new tech, but get some healthcare expertise before you decide to unleash your product on the world. We have enough problems in healthcare with unethical behavior, we don't need some whiz bang silicon valley upstarts adding to it.


And while I'm at it since I have identified this unique new breed of Unicorn, I shall give it a proper name Unicornius Gorus. The Self Goring Unicorn.



What To Make of the Senate Finance Committee's Chronic Care Policy Options


flying cadeuciiThis past December after eight months of formal work the Senate Finance Committee's "Bipartisan Chronic Care Working Group" released for comment a 30-page memo outlining 23 policy options to improve chronic care quality, patient outcomes and cost efficiency. While the Committee is not endorsing any of the options identified members will likely not stray far from this list when they move to drafting legislative language next month at least in part because members insist the bill must be cost neutral. Committee members and staff should be applauded for their effort to date since both political parties have been disinterested in adding policies to improve the Medicare program. (Last year's MACRA bill was largely unpaid for and aptly described by Henry Aaron in the New England Journal of Medicine as a log rolling exercise.) On balance, the Committee's effort should leave Medicare stakeholders cautiously hopeful. While some of the proposed options are obvious and incrementally beneficial, others might aid in innovating care delivery and in advancing CMS's efforts to improve quality and value payment.



The Obvious


Several proposed options are obvious in that they are long over due. The Committee proposes generally to improve the integration of care for individuals with a chronic disease combined with a behavioral health disorder. This proposal, possibly more than any other, could not be more welcomed. Behavioral health disorders in combination or not with chronic disease or another chronic disease are vastly under-diagnosed and under-treated. The Committee would be well served if members explored lifting billing restrictions that prohibit qualified non-physicians from treating beneficiaries with behavioral conditions. For example, there are limitations on clinical psychologists, clinical social workers and medical family therapists who are qualified but excluded from billing under the new chronic care management (CCM) code, evaluation and management codes and Health Behavior Assessment and Intervention codes. This is particularly problematic when you consider both the prevalence of behavioral health disorders and the shortage of trained behavioral health professionals.


The Committee proposes to expand telehealth services in four ways: waiving the originating site requirement for at risk ACOs; permitting MA plans to include telehealth in their annual bid amount; and, expanding its use to encourage home hemodialysis and the more timely diagnosis of stroke. The option concerning ACOs does not go far enough. There is substantial Medicaid, Veteran's Administration, Indian Health Service and commercial plan evidence, despite the Congressional Budget Office's (CBO's) contrary view, telehealth and remote monitoring services are cost efficient. Also, this proposal as currently conceived would only help five percent of ACOs, or the 22 out of 434 that are currently in an at risk track. MA plans, for example Humana, have already begun using telehealth services formally or not just through the use of any rebate dollars. Regardless, adding telehealth services to MA coverage will only add to the already considerable number of ACO program disadvantages compared to MA. (As a related aside, the inequity between these two programs certainly helps explain why providers are fleeing to MA. Nearly 60 percent of 2016 MA plan growth is attributable to provider or PSO plans.) Allowing home hemodialysis patients to receive their monthly clinical visit via telehealth would, as the Committee notes, encourage more than the 10 percent of ESRD patients that currently receive dialysis at home. The policy would also improve patient independence, quality of life and reduce beneficiary exposure to iatrogenic harm. Expanding the use of telehealth to treat stoke cannot be more welcomed particularly when you consider the woefully low rates, at less than five percent, of tPA administration to treat ischemic stroke and the profound racial disparities in stroke care.


Pancreas

Pancreas: A spongy, tube-shaped organ that is about 6 inches long and is located in the back of the abdomen, behind the stomach. The head of the pancreas is on the right side of the abdomen. It is connected to the upper end of the small intestine. The narrow end of the pancreas, called the tail, extends to the left side of the body. The pancreas makes pancreatic juices and hormones, including insulin and secretin. Pancreatic juices contain enzymes that help digest food in the small intestine. Both pancreatic enzymes and hormones are needed to keep the body working correctly. As pancreatic juices are made, they flow into the main pancreatic duct, which joins to the common bile duct, which connects the pancreas to the liver and the gallbladder and carries bile to the small intestine near the stomach. The pancreas is thus a compound gland in the sense that it is composed of both exocrine and endocrine tissues. The exocrine function of the pancreas involves the synthesis and secretion of pancreatic juices. The endocrine function resides in the million or so cellular islands (the islets of Langerhans) that are embedded between the exocrine units of the pancreas. Beta cells of the islets of Langerhans secrete insulin, which helps control carbohydrate metabolism. Alpha cells of the islets of Langerhans secrete glucagon, which counters the action of insulin.



MedTerms (TM) is the Medical Dictionary of MedicineNet.com.
We Bring Doctors' Knowledge To You

Accolade flying flag as patient advocates


I have spent years whining that no one is doing a good job helping people navigate through the maze of health care. And a survey out last week from my old firm Harris paid for by Accolade confirms that people need help. Doctors don't and can't do this. 71% of people said they trusted their doctors, but only 16% said their doctors had time to understand their life circumstances. Yet last summer a touted Silicon Valley startup called Better failed to make a go of a service doing just that.


Somehow Accolade seems to be threading this needle. They've raised more than $125m (including another $30m late last year beyond what I discuss in this interview). While they're helping patients they're charging their employers and insurers for the service. Late last summer I met Accolade's EVP Amy Loftus. In this interview she explains what they do, and how it works.